1978 W Winton Ave
Be part of pandemic-speed manufacturing for medicines
Talent is, and will always be, at the heart of our business. As part of our long-term growth strategy, we plan for significant expansion in Hayward, CA over the next 3 years. We are looking for talent to join us in various positions such as Quality Assurance, Operations, Regulatory, Engineering, Program Management, and many more.
We are one of the world's leading and most trusted suppliers to the pharmaceutical and biotech markets. We continue to break new ground within our industry, attracting global clients to our Hayward site. Rooted in the Bay Area and close to innovation in vaccines and therapeutics, we provide state-of-the-art, single-use manufacturing technology to support our customers with their clinical programs and through to commercial launch. Whether our customers are developing life-saving therapies for cancer or potential treatments for COVID-19, we can support them with world class manufacturing and process excellence.
With a history that dates back to 1897, Lonza is a trusted name with a wealth of knowledge and expertise in life science. Today we are more than 15,000 employees in more than 100 locations around the world. Together in 2019, we supported the development and production of over 1000 therapies.
We offer you exposure to upcoming biotech and established pharmaceutical companies and to the manufacturing technology needed to produce the potential blockbuster treatments of tomorrow. While other companies may only offer you the opportunity to work on a few treatments, at Lonza you will be working on scores of treatments per year for a variety of customers.
We are here to make a meaningful difference. It is the foundation of the way we do business. Looking after our people, our customers, our planet is core to our purpose. A career at Lonza is more than a job. We do not just work in the life sciences industries, we are transforming it. What we do today is helping to create a healthier, happier world tomorrow. That’s the meaningful difference we make every day.
206 articles with Lonza
The new agreement will provide Lonza with access to Arbor’s gene editing technology Quote from David Cheng, CEO of Arbor: “Arbor's differentiated gene editing technologies allow Lonza to manufacture the next generation of therapeutics. Arbor is committed to seeking and working with partners in this field to build an ecosystem for the research, development and manufacturing of biological and cellular therapies.”
Lonza and Be The Match BioTherapies Partner to Expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network
Be The Match BioTherapies as a preferred partner to provide consistent access to high-quality, healthy donor tissue and cell and gene therapy (CGT) supply chain support
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab
In an effort to change the course of this pandemic, advancing lead COVID-19 therapeutics requires matched supply chain efforts and expertise to meet the continued and urgent patient needs.
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing
- Lonza to utilize of IsoPlexis' IsoLight® automated proteomics platform - IsoLight® to be used for functional quality analytics for cell therapy products produced on Lonza's Cocoon® Platform, an automated cell manufacturing platform [20-August-2020] BASEL, Switzerland and BRANFORD, Conn. , Aug. 20, 2020 /PRNewswire/ -- Quote from Matthew Hewitt , Hea
Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine against the novel coronavirus and additional Moderna products in the future.
As the situation progresses, they hope to establish more production suites across Lonza’s facilities globally, with a goal of manufacturing up to 1 billion doses of mRNA-1273 per year at the currently expected dose of 50 µg.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials
XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat kidney disease announces that it has granted the manufacturing contract for the active pharmaceutical ingredient for XRx-101 and XRx-008 to Lonza Pharma & Biotech.
Free Lonza webinar to discuss the benefits of using physiologically relevant 3D cell culture models to enhance respiratory research for diseases like COVID-19
Lonza Launches New TheraPEAK™ SfAAV™ Medium to Boost and Optimize the Production of AAV in Sf9 Insect Cells
Lonza has launched a new medium to enhance and accelerate the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells
Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors
Collaboration between Triumvira Immunologics and Lonza will leverage the innovative Cocoon® Platform for novel TAC01-HER2 program
Lonza Collaborates with Immunotherapy Leaders to Assess Point-of-Care Manufacturing for Cancer Cell Therapies
“We are extremely motivated to be working hand-in-hand with these premier institutes, among the leaders in cell-based immunotherapy discovery and development, to exhibit the use of the closed, automated Cocoon® Platform for manufacturing cell therapies.
Albert Baehny, chairman of the board of directors, said the company looks forward to the coming challenges of 2020, including the naming of a new CEO.
Lonza’s New eCHO™ Basal Medium and Feed Facilitates Late-Stage Cell Viability and a Consistent Yield of High Integrity Proteins
Results demonstrating the performance of the eCHO™ Medium will be presented at the 2019 PEGS Europe and Antibody Engineering and Therapeutics conferences
Lonza announced that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found.
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy
Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis
Lonza to Host New Webinar – “Paper to EBR in 9 Months: How a Strong Collaboration Leads to Project Success”
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform
Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
Mesoblast and Lonza announced that they have entered into an agreement for commercial manufacture of Mesoblast’s lead allogeneic cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease
Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months